ROCHE PRODUCTS INDIA PVT LTD

For Mumbai-based Roche Products India, a revenue of Rs 13 crore was generated in the biopharma space during FY 20-21. This marks a growth of 33 per cent for the company in comparison to the revenue generation of Rs 9 crore in the previous fiscal. Owing to the pandemic during FY 20-21, the company observed an unprecedented demand for Tocilizumab (Actemra) given the significant increase in COVID-19 cases across India. The company responded to this situation with supplies of the medicine to meet the immediate emergency demand. Roche partnered with Cipla for the marketing and distribution of Tocilizumab.